The Laryngoscope,
Год журнала:
2024,
Номер
135(2), С. 729 - 740
Опубликована: Окт. 8, 2024
Objective
Investigate
missed
adjuvant
therapy
and
associated
disparities
in
overall
survival
(OS)
for
human
papillomavirus‐associated
(HPV+)
oropharyngeal
squamous
cell
carcinoma
(OPSCC).
Methods
The
2010–2017
National
Cancer
Database
was
queried
patients
with
surgically
resected
HPV+
OPSCC.
Indications
radiotherapy
(aRT)
included
pT3‐4
classification,
pN2‐3
lymphovascular
invasion,
pathologic
extranodal
extension
(pENE),
and/or
positive
surgical
margins
(PSM).
Indication(s)
chemoradiotherapy
(aCRT)
pENE
PSM.
Multivariable
logistic
Cox
regression
models
were
implemented.
Results
Of
5297
satisfying
inclusion
criteria,
4288
had
indication(s)
aRT;
775
did
not
receive
any
considered
as
missing
aRT.
A
total
of
2234
aCRT.
these,
1383
(61.9%)
received
aCRT,
555
(24.8%)
aRT
alone
having
296
(13.2%)
therapy.
Missed
aCRT
each
age,
treatment
facility
type,
pN
margin
status
(
p
<
0.015).
Among
alone,
OS
those
receiving
no
therapy,
90.0%,
94.8%,
93.4%,
respectively
=
0.080).
similar
(89.0%
vs.
86.6%,
0.357)
which
superior
to
(74.9%,
0.001).
These
patterns
persisted
on
multivariable
regression.
Conclusion
OPSCC
aRT,
worse
OS.
For
Level
Evidence
3
Laryngoscope
,
135:729–740,
2025
Journal of Clinical Oncology,
Год журнала:
2024,
Номер
42(8), С. 940 - 950
Опубликована: Янв. 19, 2024
PURPOSE
Standard
curative-intent
chemoradiotherapy
for
human
papillomavirus
(HPV)–related
oropharyngeal
carcinoma
results
in
significant
toxicity.
Since
hypoxic
tumors
are
radioresistant,
we
posited
that
the
aerobic
state
of
a
tumor
could
identify
patients
eligible
de-escalation
while
maintaining
treatment
efficacy.
METHODS
We
enrolled
with
HPV-related
to
receive
de-escalated
definitive
phase
II
study
(ClinicalTrials.gov
identifier:
NCT03323463
).
Patients
first
underwent
surgical
removal
disease
at
their
primary
site,
but
not
gross
neck.
A
baseline
18
F-fluoromisonidazole
positron
emission
tomography
scan
was
used
measure
hypoxia
and
repeated
1-2
weeks
intratreatment.
nonhypoxic
received
30
Gy
(3
weeks)
chemotherapy,
whereas
those
standard
70
(7
weeks).
The
objective
achieving
2-year
locoregional
control
(LRC)
95%
7%
noninferiority
margin.
RESULTS
One
hundred
fifty-eight
T0-2/N1-N2c
were
enrolled,
which
152
analyses.
Of
these,
128
met
criteria
24
Gy.
LRC
94.7%
(95%
CI,
89.8
97.7),
meeting
our
objective.
With
median
follow-up
time
38.3
(range,
22.1-58.4)
months,
progression-free
survival
(PFS)
overall
(OS)
rates
94%
100%,
respectively,
30-Gy
cohort.
70-Gy
cohort
had
similar
PFS
OS
96%
96%,
respectively.
Acute
grade
3-4
adverse
events
more
common
versus
(58.3%
v
32%;
P
=
.02).
Late
only
occurred
cohort,
4.5%
complained
late
dysphagia.
CONCLUSION
Tumor
is
promising
approach
direct
dosing
carcinomas
preserved
efficacy
substantially
reduced
toxicity
requires
further
investigation.
Biomedicines,
Год журнала:
2023,
Номер
11(4), С. 1099 - 1099
Опубликована: Апрель 5, 2023
Cluster
of
differentiation
44
(CD44)
has
been
investigated
as
a
cancer
stem
cell
(CSC)
marker
it
plays
critical
roles
in
tumor
malignant
progression.
The
splicing
variants
are
overexpressed
many
carcinomas,
especially
squamous
and
play
the
promotion
metastasis,
acquisition
CSC
properties,
resistance
to
treatments.
Therefore,
each
CD44
variant
(CD44v)
function
distribution
carcinomas
should
be
clarified
for
establishment
novel
diagnosis
therapy.
In
this
study,
we
immunized
mouse
with
(CD44v3–10)
ectodomain
established
various
anti-CD44
monoclonal
antibodies
(mAbs).
One
clones
(C44Mab-34;
IgG1,
kappa)
recognized
peptide
that
covers
both
7-
8-encoded
regions,
indicating
C44Mab-34
is
specific
mAb
CD44v7/8.
Moreover,
reacted
CD44v3–10-overexpressed
Chinese
hamster
ovary-K1
(CHO)
cells
or
oral
carcinoma
(OSCC)
line
(HSC-3)
by
flow
cytometry.
apparent
KD
CHO/CD44v3–10
HSC-3
was
1.4
×
10−9
3.2
M,
respectively.
could
detect
CD44v3–10
Western
blotting
stained
formalin-fixed
paraffin-embedded
OSCC
immunohistochemistry.
These
results
indicate
useful
detecting
CD44v7/8
applications
expected
application
Frontiers in Oncology,
Год журнала:
2025,
Номер
15
Опубликована: Фев. 19, 2025
The
integration
of
viral
DNA
into
the
human
genome
is
a
critical
event
in
pathogenesis
various
cancers.
This
process
leads
to
genomic
instability,
disrupts
cellular
regulatory
mechanisms,
and
activates
oncogenes
or
inactivates
tumor
suppressor
genes.
Despite
significant
advancements
sequencing
technologies,
there
remains
notable
lack
computational
tools,
particularly
web-based
applications,
specifically
designed
for
analysis
visualization.
To
address
this
gap,
we
present
virusPlot,
web
server
with
following
functional
modules:
(i)
automatic
retrieval
virus
sequences
their
annotation;
(ii)
visualization
locations
read
counts
through
graphical
representation
that
links
host
sites,
facilitating
interpretation
patterns;
(iii)
hotspots
using
Fisher's
exact
test;
(iv)
functions
an
interactive
platform
via
shinyapp.
VirusPlot
efficiently
processes
visualizes
data
from
viruses
genomes,
providing
researchers
intuitive
user-friendly
analytical
tool
simplifies
complexity
analysis.
Current Opinion in Oncology,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 20, 2025
Purpose
of
review
Osteoradionecrosis
may
often
be
prevented
in
context
interprofessional
healthcare
that
includes
dental
specialists
prior
to
and
following
completion
the
patient's
head
neck
radiation
therapy.
Important
factors,
however,
compromise
delivery
guideline-concordant
management
osteoradionecrosis
(ORN),
including
patient
access
this
care.
This
is
directed
these
related
issues,
order
foster
enhanced
approaches
for
ORN
management.
Recent
findings
The
centered
2024
Journal
Clinical
Oncology
publication
‘Prevention
Management
Patients
With
Head
Neck
Cancer
Treated
Radiation
Therapy:
ISOO-MASCC-ASCO
Guideline’,
companion
JCO
Practice
which
clinical
insights
guideline
are
addressed.
Key
recent
literature
cited
provide
contemporary
decision-making
prevention
early
diagnosis
treatment
ORN.
Although
a
relatively
infrequent
complication
patients,
can
have
profound
financial
impact
when
it
occurs.
Summary
Interprofessional
oncology
care
essential
Future
research
needed
enhance
management,
studies
predicting
risk
development
based
on
patient-centered
factors.
Pathogens,
Год журнала:
2025,
Номер
14(3), С. 289 - 289
Опубликована: Март 15, 2025
Human-papillomavirus-positive
oropharyngeal
squamous
cell
carcinoma
(HPV-positive
OPSCC)
is
a
distinct
disease
characterized
by
unique
clinical
and
molecular
features
compared
to
HPV-negative
OPSCC.
A
comprehensive
bibliometric
analysis
of
HPV-positive
OPSCC
research
was
conducted
in
this
study
identify
key
trends,
hotspots,
emerging
frontiers
the
field.
Data
were
retrieved
from
Web
Science
Core
Collection
database.
The
distributions
contributors,
including
countries,
institutions,
authors,
journals,
cooperative
networks
related
OPSCC,
analyzed
visualized
using
VOSviewer
1.6.20,
CiteSpace
6.3.R1,
R
package
Bibliometrix
4.0.0.
In
addition,
most
influential
publications
high-frequency
keywords
identified
discern
topics
total
3895
articles
reviews
on
identified,
involving
106
620
18949
authors.
main
contributors
include
USA
(1908
publications),
Johns
Hopkins
University
(310
journal
Head
Neck
(320
Erich
M.
Sturgis
(94
publications).
top
three
are
“survival”,
“radiotherapy”,
“p16”.
There
has
been
steadily
increasing
interest
over
last
23
years.
Current
studies
focus
diagnosis,
treatment
strategies,
prognosis,
recurrence,
surveillance.
This
highlights
themes,
offering
insights
for
future
directions.